Jeito Capital leads a USD 65 million Series A financing in ReproNovo to advance treatments in reproductive medicine and women's health.
Jeito Capital leads a USD 65 million Series A financing in ReproNovo to advance treatments in reproductive medicine and women's health.
05/21/25, 5:45 AM
Location
lausanneMoney raised
$65 million
Industry
biotechnology
health care
Round Type
series a
Investors
Alsa Ventures, Ysios Capital, M Ventures, Axa Im Alts, Jeito Capital
Jeito Capital is leading a USD 65 million Series A financing round in ReproNovo to support clinical trials for its candidates RPN-001 and RPN-002. This investment highlights Jeito's commitment to innovative biopharma solutions. The funding aims to address growing infertility issues worldwide. Ksenija Pavletic from Jeito will join ReproNovo's Board of Directors.
Company Info
Location
lausanne, vaud, switzerland
Additional Info
ReproNovo is a cutting-edge biopharmaceutical company identifying and developing innovative solutions to address critical gaps in reproductive medicine and women’s health. Our team is composed of proven experts with deep experience in reproductive medicine, drug development, regulatory affairs and business development who have throughout their careers successfully brought multiple therapies to market. Lead clinical compound, RPN-001 (leflutrozole), is initially being developed to treat male infertility. RPN-002 (nolasiban) is a first-in-disease and first-in-class molecular entity to manage adenomyosis and increase the probability of embryo implantation in women undergoing assisted reproductive technology (ART) treatments. Both assets are Phase 2 ready. ReproNovo is financed by Jeito Capital, AXA IM Alts, founding investor M Ventures, Ysios Capital and ALSA Ventures.